Ian Churcher
CEO & Founder Janus Drug Discovery Consulting Ltd
Ian was one of the pioneers of the therapeutic PROTAC field through his 2012 collaboration with Prof Craig Crews & Alessio Ciulli when leading the GSK PROTAC group (2012-2017) including the publication of the landmark 2015 Nature Chemical Biology paper and advancing a portfolio of PROTACs towards the clinic. Subsequently, Ian has also been CSO at TPD biotech Amphista therapeutics, advancing a series of DCAF16-dependent degraders towards the clinic. Ian also has extensive experience of medicinal chemistry & chemical biology leadership from roles at Merck & GSK across many therapy areas including neuroscience, oncology & inflammation. Since 2024, Ian has been an independent consultant providing advice in TPD and other areas to a range of pharma, biotech, academic & investor groups.
Seminars
Join academic KOLs for a discussion on things yet to come for induced proximity therapeutics. Expect to cover next-generation PROTACs, degrader
antibody conjugates, the new focus on cooperative molecular glues, and non-degrading proximity therapeutics. This will be a chance to hear about the latest academic research, opportunities for growth in biopharma, and first-hand opinions from leading pioneers on where the TPD and induced proximity community is headed.
